Shaaban Sherif G, Khan Mohammed K, Savage Natasha, Yan Weisi, Pishgou Mahboubeh, Davis Loretta, Mourad Waleed F
{"title":"Total Skin Electron Irradiation (TSEI) May Induce Systemic Progression of Mycosis Fungoides (MF) - Cutaneous T-Cell Lymphoma (CTCL)","authors":"Shaaban Sherif G, Khan Mohammed K, Savage Natasha, Yan Weisi, Pishgou Mahboubeh, Davis Loretta, Mourad Waleed F","doi":"10.36959/661/301","DOIUrl":null,"url":null,"abstract":"The management of MF-CTCL is based on a 'stage-based' approach and an evaluation by a multidisciplinary team is preferred. Initial treatment in patients with local (patch/plaque) disease includes skin-directed therapies (localized or generalized), with the addition of systemic biologic therapy for refractory, or progressive disease. In patients with unfavorable prognostic features (e.g., folliculotropic or large-cell transformed MF, or B1 involvement) systemic biologic therapies may be introduced earlier in the treatment algorithm.","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"83 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36959/661/301","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
The management of MF-CTCL is based on a 'stage-based' approach and an evaluation by a multidisciplinary team is preferred. Initial treatment in patients with local (patch/plaque) disease includes skin-directed therapies (localized or generalized), with the addition of systemic biologic therapy for refractory, or progressive disease. In patients with unfavorable prognostic features (e.g., folliculotropic or large-cell transformed MF, or B1 involvement) systemic biologic therapies may be introduced earlier in the treatment algorithm.